Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

AbbVie announced Monday that it is buying Aliada Therapeutics, along with its lead drug candidate ALIA-1758 — an experimental antibody being tested for treating Alzheimer’s disease ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups look to build on former ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on ...

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

LATEST NEWS 07:15 Live News: Asian markets update; Fianna Fáil, Fine Gael and Sinn Féin’s housing plans rated 05:00 Comer brothers told to change plans for apartments next to Maynooth church 05:00 ...

Are you a print subscriber? Activate your account. By Adrianne Pasquarelli - 2 hours 3 min ago By Erika Wheless - 2 hours 3 min ago By Brian Bonilla - 2 hours 3 min ago By Tim Nudd - 2 hours 3 min ...

In the last three months, 11 analysts have published ratings on AbbVie (NYSE:ABBV), offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 million upfront to form a new drug discovery pact with Gedeon Richter.